Nicholas Turner, Professor of Molecular Oncology at the Institute of Cancer Research, is an gifted Medical Oncologist who has excelled in the research, development and application of cutting-edge molecular technology for breast cancer management.
His major achievements fall into two categories – (i) CDK4/6 inhibition: his clinical trial of fulvestrant±palbociclib. He designed this on the basis of laboratory observations and led the investigator-initiated trial resulting in NICE approval of the combined treatment for advanced breast cancer in 2020.
(ii) ctDNA: his advances in the early detection of recurrent disease and of targetable mutations in ctDNA acting as a liquid biopsy. These innovative advances are at the forefront of a revolution in the personalisation of breast cancer management.